NASDAQ$WBA
Walgreens Boots Alliance Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Walgreens reported a mixed second quarter with sales growth offset by a net loss due to impairment charges, while adjusted EPS increased slightly.
Walgreens Boots Alliance (WBA) announced its fiscal 2024 second quarter results, revealing a 6.3% increase in sales to $37.1 billion, but a net loss of $5.9 billion due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Adjusted EPS increased by 3.4% to $1.20. The company narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35.
- Sales increased 6.3% year-over-year to $37.1 billion, or 5.7% on a constant currency basis.
- Loss per share was $6.85, compared to earnings per share of $0.81 in the year-ago quarter, impacted by a $5.8 billion after-tax non-cash impairment charge.
- Adjusted EPS increased 3.4% to $1.20, or 2.8% on a constant currency basis.
- Fiscal 2024 adjusted EPS guidance narrowed to $3.20 to $3.35.
Headline financials
Revenue & EPS history
Walgreens · Revenue · Quarterly
$37.1B
Revenue by segment
Walgreens · $7.76B total across 2 segments · Q4 2023
- International$5.78B—74.6%
- U.S. Healthcare$1.97B+217.0%25.4%
Forward guidance
Walgreens Boots Alliance narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, reflecting challenges in the retail environment, the early wind-down of the sale-leaseback program, and lower earnings due to Cencora share sales, offset by pharmacy services execution and a lower adjusted effective tax rate.
Tailwinds
- Execution in pharmacy services is expected to offset some challenges.
- A lower adjusted effective tax rate is anticipated.
- U.S. Healthcare adjusted EBITDA is maintained to be breakeven at the midpoint of the guidance range.
- Company confident in goal of achieving $1 billion in cost savings this year.
- Team members are powering progress as we map growth opportunities.
Headwinds
- Challenging retail environment in the U.S. is impacting performance.
- Early wind-down of the sale-leaseback program is creating headwinds.
- Lower earnings are expected due to Cencora share sales.
- Operating cash flow was negatively impacted by payments related to legal matters.
- Softer U.S. retail performance and lower sale-leaseback gains, partly offset by improved profitability in the U.S. Healthcare segment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q2 2024
-0.1%
Avg return
Earnings day
+0.4%
Avg return
5 days after
-1.9%
Avg return
30 days after
53%
33 / 62 earnings
Positive
+29.1%
Q1 2025
Best reaction
-22.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.4% | +1.5% | +2.7% | |
| Q2 2025 | -1.1% | +0.5% | +4.1% | |
| Q1 2025 | +29.1% | +36.1% | +10.0% | |
| Q4 2024 | +23.0% | +18.7% | -2.0% | |
| Q3 2024 | -22.7% | -26.0% | -24.5% | |
| Q2 2024 | -7.0% | -10.9% | -15.7% | |
| Q1 2024 | -2.2% | -0.6% | -11.4% | |
| Q4 2023 | +2.9% | +2.1% | -7.3% | |
| Q3 2023 | -7.9% | -10.2% | -3.0% | |
| Q2 2023 | +3.7% | +5.0% | +6.6% | |
| Q1 2023 | -2.3% | -2.1% | -1.1% | |
| Q4 2022 | +4.1% | +3.8% | +29.4% | |
| Q3 2022 | -5.7% | -5.7% | -2.9% | |
| Q2 2022 | -7.6% | -8.4% | -10.6% | |
| Q1 2022 | -0.3% | +0.6% | -10.0% | |
| Q4 2021 | +3.5% | +1.5% | +4.8% | |
| Q3 2021 | -8.4% | — | — | |
| Q2 2021 | +3.3% | — | — | |
| Q1 2021 | +5.1% | — | — | |
| Q4 2020 | +4.2% | — | — | |
| Q3 2020 | -5.1% | — | — | |
| Q2 2020 | -5.4% | — | — | |
| Q1 2020 | -7.8% | — | — | |
| Q4 2019 | +1.5% | — | — | |
| Q3 2019 | +4.4% | — | — | |
| Q2 2019 | -13.6% | — | — | |
| Q1 2019 | -8.2% | — | — | |
| Q4 2018 | +1.6% | — | — | |
| Q3 2018 | -9.4% | — | — | |
| Q2 2018 | -0.7% | — | — | |
| Q1 2018 | -3.4% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +1.6% | — | — | |
| Q2 2017 | -1.0% | — | — | |
| Q1 2017 | +0.1% | — | — | |
| Q4 2016 | +5.7% | — | — | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | -3.0% | — | — | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -11.9% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q2 2015 | +4.9% | — | — | |
| Q4 2013 | +4.9% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q2 2013 | +0.4% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | -3.2% | — | — | |
| Q2 2012 | -1.9% | — | — | |
| Q1 2012 | +4.1% | — | — | |
| Q4 2011 | +0.4% | — | — | |
| Q3 2011 | -0.9% | — | — | |
| Q2 2011 | +1.8% | — | — | |
| Q1 2010 | +2.5% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2010 | -0.1% | — | — | |
| Q2 2009 | +0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro